David Clayton Sutherland

Title: David Clayton Sutherland: Innovator in Pharmaceutical Compositions

Introduction

David Clayton Sutherland is a notable inventor based in Little Rock, Arkansas. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug compositions aimed at treating gastrointestinal conditions. With a total of four patents to his name, Sutherland's work has the potential to impact many lives.

Latest Patents

Sutherland's latest patents include innovative pharmaceutical compositions that incorporate omeprazole and a benzimidazole drug. These compositions are designed for oral administration and are intended to treat various gastrointestinal conditions. Another patent focuses on compositions that include a proton pump inhibitor and an antiparasitic drug, which can also be formulated for oral administration. Both patents describe methods of treatment using these compositions, showcasing Sutherland's commitment to advancing medical science.

Career Highlights

Throughout his career, Sutherland has been associated with Adamis Pharmaceuticals Corporation, where he has played a crucial role in research and development. His expertise in pharmaceutical formulations has contributed to the company's mission of providing effective treatments for patients.

Collaborations

Sutherland has collaborated with notable colleagues, including James Kyle Zorn and Dennis J Carlo. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

David Clayton Sutherland is a distinguished inventor whose work in pharmaceutical compositions is paving the way for new treatments in gastrointestinal health. His contributions to the field are invaluable and reflect his dedication to improving patient outcomes.